Table 2. Baseline characteristics of individuals included in the present study.
| Variables | Controls (n = 225) | Spontaneous clearance (n = 189) | Persistent infection (n = 173) | P |
| Age(mean±SD) | 31.81±8.09 | 32.43±6.15 | 32.63±6.18 | 0.457a |
| Duration of drug use(mean±SD) | 3.72±4.14 | 6.43±3.79 | 7.22±4.31 | 0.000 a |
| Gender | ||||
| male | 157(69.8) | 126(66.7) | 123(71.1) | |
| female | 68(30.2) | 63(33.3) | 50(28.9) | 0.639 b |
| IDU | ||||
| yes | 73(32.4) | 161(85.2) | 137(79.2) | |
| no | 152(67.6) | 28(14.8) | 36(20.8) | 0.000 b |
| LMP2 | ||||
| Arg | 357(79.3) | 295(78.5) | 276(79.8) | |
| His | 93(20.7) | 81(21.5) | 70(20.2) | 0.906 b |
| LMP7 | ||||
| Gin | 371(82.4) | 233(67.3) | 289(76.5) | |
| Lys | 79(17.6) | 113(32.7) | 89(23.5) | o.ooo b |
a: one-way ANOVA; b: χ2 test.
[n (%)]